Sundry Images
Gilead’s (NASDAQ:GILD) Kite unit reported optimistic outcomes from a five-year follow-up of a Section 2 research for its cell remedy Yescarta in sure sufferers with non-Hodgkin lymphoma, or NHL.
The evaluation confirmed that after a median follow-up of greater than
